STVN
Bearish signalScored 2026-10-04 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Stevanato Group S.p.A.
- Nom
- Stevanato Group S.p.A.
- Secteur
- Healthcare
- Industrie
- Medical - Instruments & Supplies
- Bourse
- NYSE
- Capitalisation
- $5.3B
- Employés
- 6,010
- PDG
- Franco Stevanato
- Site web
- https://www.stevanatogroup.com
- Marché
- ATRAVTRAXSMBLCOBTSGCHE
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 4 068 titres (~81 726,12 $ US)
- Insiders
- Santel LucianoMagistretti Elisabetta
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$459,738
Avg sell (VWAP, 90d window) $20.97 vs last close $19.86 (-5.3%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-07
- Liquidity
- Thin $6,640,374/day · 20d vol
- Last synced
-
2026-10-06 21:10:56
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-28 | Stocchi Mauro | Sell · S | 13,649 | $21.50 | $293,454 | Form 4 |
| 2026-08-07 | Dal Lago Marco | Sell · S | 4,209 | $20.09 | $84,559 | Form 4 |
| 2026-08-07 | Magistretti Elisabetta | Sell · S | 2,045 | $20.09 | $41,084 | Form 4 |
| 2026-08-07 | Santel Luciano | Sell · S | 2,023 | $20.09 | $40,642 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-04 Drivers: fundamentals. Moteurs : fondamentaux.
STVN presents a moderate opportunity driven by a confirmed Q2 2026 earnings beat and new regulatory authorizations for Liraglutide products, but financial health scores (liquidity: 65, fundamentals trend: 55) reflect an…
The first sentence of the analysis written for STVN on 2026-10-04 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. Weekly bias is flat
- Financial indicators Supports a bullish reading. Current ratio 1.74 · operating margin 16%
Suggested stop 18.30, nearest stored support minus 0.5 ATR(7.8% under the last close). Reward/risk to the next stored resistance is 0.73. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 29.0% | 27.4% | 31.3% | 32.5% | 31.4% | |
| Ebit Margin | 17.9% | 15.1% | 17.9% | 19.5% | 20.2% | |
| Ebitda Margin | 25.3% | 22.4% | 25.1% | 26.1% | 26.9% | |
| Operating Profit Margin | 16.1% | 14.6% | 18.5% | 19.6% | 19.2% | |
| Pretax Profit Margin | 15.9% | 14.5% | 17.5% | 19.1% | 19.6% | |
| Continuous Operations Profit Margin | 11.8% | 10.7% | 13.4% | 14.5% | 15.9% | |
| Net Profit Margin | 11.8% | 10.7% | 13.4% | 14.5% | 15.9% | |
| Bottom Line Profit Margin | 11.8% | 10.7% | 13.4% | 14.5% | 15.9% | |
| Current Ratio | 1.745 | 1.843 | 1.501 | 1.829 | 2.557 | |
| Quick Ratio | 1.244 | 1.330 | 1.056 | 1.368 | 2.118 | |
| Solvency Ratio | 0.208 | 0.215 | 0.239 | 0.313 | 0.330 | |
| Cash Ratio | 0.244 | 0.206 | 0.121 | 0.495 | 1.214 | |
| Price To Earnings Ratio | 34.947 | 48.936 | 44.890 | 31.664 | 37.250 | |
| Price To Earnings Growth Ratio | 2.505 | -2.243 | 11.896 | 0.000 | 0.417 | |
| Forward Price To Earnings Growth Ratio | 2.505 | -2.243 | 11.896 | 0.000 | 0.417 | |
| Price To Earnings Diluted Ratio | 34.947 | 48.936 | 44.890 | 31.664 | 37.250 | |
| Price To Earnings Diluted Growth Ratio | 2.505 | -2.243 | 11.896 | 0.000 | 0.417 | |
| Price To Book Ratio | 3.146 | 4.089 | 5.776 | 4.459 | 6.206 | |
| Price To Sales Ratio | 4.103 | 5.201 | 6.027 | 4.516 | 6.192 | |
| Price To Free Cash Flow Ratio | 218.045 | -36.388 | -19.427 | -31.772 | 259.270 | |
| Price To Operating Cash Flow Ratio | 17.013 | 36.860 | 62.175 | 42.998 | 39.193 | |
| Debt To Assets Ratio | 0.185 | 0.184 | 0.191 | 0.132 | 0.172 | |
| Debt To Equity Ratio | 0.317 | 0.305 | 0.350 | 0.219 | 0.290 | |
| Debt To Capital Ratio | 0.241 | 0.234 | 0.259 | 0.180 | 0.225 | |
| Long Term Debt To Capital Ratio | 0.185 | 0.179 | 0.176 | 0.118 | 0.179 | |
| Financial Leverage Ratio | 1.711 | 1.658 | 1.829 | 1.666 | 1.685 | |
| Working Capital Turnover Ratio | 2.843 | 3.199 | 3.236 | 2.160 | 2.398 | |
| Operating Cash Flow Ratio | 0.513 | 0.326 | 0.183 | 0.223 | 0.394 | |
| Operating Cash Flow Sales Ratio | 0.241 | 0.141 | 0.097 | 0.105 | 0.158 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.078 | -1.013 | -3.200 | -1.353 | 0.151 | |
| Debt Service Coverage Ratio | 1.681 | 1.805 | 1.633 | 3.088 | 4.651 | |
| Interest Coverage Ratio | 8.396 | 23.476 | 46.517 | 48.890 | 33.304 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.258 | 1.458 | 0.776 | 1.598 | 3.587 | |
| Operating Cash Flow Coverage Ratio | 0.584 | 0.363 | 0.265 | 0.473 | 0.546 | |
| Capital Expenditure Coverage Ratio | 1.085 | 0.497 | 0.238 | 0.425 | 1.178 | |
| Dividend Paid And Capex Coverage Ratio | 1.027 | 0.475 | 0.231 | 0.403 | 1.072 | |
| Dividend Payout Ratio | 0.105 | 0.123 | 0.098 | 0.095 | 0.083 | |
| Enterprise Value Multiple | 17.381 | 24.506 | 25.219 | 17.285 | 22.294 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 29.0% | ▲1.6% | ▼-1.3% |
| Ebit Margin | 17.8% | ▲2.7% | ▼-0.2% |
| Ebitda Margin | 25.3% | ▲2.9% | ▲0.2% |
| Operating Profit Margin | 16.1% | ▲1.5% | ▼-1.5% |
| Pretax Profit Margin | 15.9% | ▲1.4% | ▼-1.4% |
| Continuous Operations Profit Margin | 11.8% | ▲1.1% | ▼-1.5% |
| Net Profit Margin | 11.8% | ▲1.1% | ▼-1.5% |
| Bottom Line Profit Margin | 11.8% | ▲1.1% | ▼-1.5% |
| Current Ratio | 1.745 | ▼-0.099 | ▼-0.150 |
| Quick Ratio | 1.244 | ▼-0.086 | ▼-0.179 |
| Solvency Ratio | 0.208 | ▼-0.007 | ▼-0.053 |
| Cash Ratio | 0.244 | ▲0.038 | ▼-0.212 |
| Price To Earnings Ratio | 34.947 | ▼-13.989 | ▼-4.590 |
| Price To Earnings Growth Ratio | 2.505 | ▲4.747 | ▼-0.010 |
| Forward Price To Earnings Growth Ratio | 2.505 | ▲4.747 | ▼-0.010 |
| Price To Earnings Diluted Ratio | 34.947 | ▼-13.989 | ▼-4.590 |
| Price To Earnings Diluted Growth Ratio | 2.505 | ▲4.747 | ▼-0.010 |
| Price To Book Ratio | 3.146 | ▼-0.942 | ▼-1.589 |
| Price To Sales Ratio | 4.103 | ▼-1.098 | ▼-1.105 |
| Price To Free Cash Flow Ratio | 218.045 | ▲254.433 | ▲140.099 |
| Price To Operating Cash Flow Ratio | 17.013 | ▼-19.847 | ▼-22.635 |
| Debt To Assets Ratio | 0.185 | ▲0.001 | ▲0.012 |
| Debt To Equity Ratio | 0.317 | ▲0.011 | ▲0.020 |
| Debt To Capital Ratio | 0.241 | ▲0.007 | ▲0.013 |
| Long Term Debt To Capital Ratio | 0.185 | ▲0.007 | ▲0.018 |
| Financial Leverage Ratio | 1.711 | ▲0.053 | ▲0.001 |
| Working Capital Turnover Ratio | 2.843 | ▼-0.356 | ▲0.076 |
| Operating Cash Flow Ratio | 0.513 | ▲0.187 | ▲0.185 |
| Operating Cash Flow Sales Ratio | 0.241 | ▲0.100 | ▲0.093 |
| Free Cash Flow Operating Cash Flow Ratio | 0.078 | ▲1.091 | ▲1.145 |
| Debt Service Coverage Ratio | 1.681 | ▼-0.125 | ▼-0.891 |
| Interest Coverage Ratio | 8.396 | ▼-15.080 | ▼-23.720 |
| Short Term Operating Cash Flow Coverage Ratio | 2.258 | ▲0.800 | ▲0.323 |
| Operating Cash Flow Coverage Ratio | 0.584 | ▲0.221 | ▲0.138 |
| Capital Expenditure Coverage Ratio | 1.085 | ▲0.588 | ▲0.400 |
| Dividend Paid And Capex Coverage Ratio | 1.027 | ▲0.552 | ▲0.386 |
| Dividend Payout Ratio | 0.105 | ▼-0.017 | ▲0.005 |
| Enterprise Value Multiple | 17.381 | ▼-7.125 | ▼-3.956 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $4.67B | $5.74B | $6.54B | $4.44B | $5.23B | |
| Enterprise value | $5.02B | $6.07B | $6.87B | $4.43B | $5.06B | |
| EV / Sales | 4.40x | 5.50x | 6.33x | 4.50x | 6.00x | |
| EV / Op. cash flow | 18.25x | 38.98x | 65.28x | 42.90x | 37.94x | |
| EV / Free cash flow | 233.91x | -38.48x | -20.40x | -31.70x | 251.00x | |
| EV / EBITDA | 17.38x | 24.51x | 25.22x | 17.29x | 22.29x | |
| Net debt / EBITDA | 1.18x | 1.33x | 1.20x | -0.04x | -0.73x | |
| Current ratio | 1.75x | 1.84x | 1.50x | 1.83x | 2.56x | |
| Income quality | 2.05x | 0.97x | 0.56x | 0.55x | 0.81x | |
| Graham number | $8 | $7 | $7 | $7 | $6 | |
| Graham net-net | -$1 | -$1 | -$1 | -$0 | $1 | |
| Tax burden | 73.9% | 73.5% | 76.8% | 76.1% | 81.1% | |
| Interest burden | 89.3% | 95.9% | 97.8% | 97.9% | 97.1% | |
| Working capital | $398.8M | $402.6M | $287.5M | $383.3M | $527.3M | |
| Invested capital | $1.89B | $1.75B | $1.42B | $1.12B | $1.02B | |
| Return on assets | 5.3% | 5.1% | 7.0% | 8.6% | 9.5% | |
| Operating ROA | 7.5% | 7.3% | 10.8% | 12.5% | 13.6% | |
| Return on tangible assets | 5.5% | 5.2% | 7.3% | 9.0% | 10.0% | |
| Return on equity | 9.0% | 8.4% | 12.9% | 14.3% | 16.0% | |
| Return on invested capital | 6.4% | 6.0% | 9.4% | 11.6% | 11.7% | |
| Return on capital employed | 9.1% | 8.7% | 13.4% | 16.1% | 15.0% | |
| Earnings yield | 2.9% | 2.1% | 2.2% | 3.2% | 2.6% | |
| Free cash flow yield | 0.5% | -2.7% | -5.1% | -3.1% | 0.4% | |
| Capex / Op. cash flow | 92.2% | 201.3% | 420.0% | 235.3% | 84.9% | |
| Capex / Depreciation | 302.0% | 388.8% | 563.1% | 375.1% | 200.7% | |
| Capex / Sales | 22.2% | 28.4% | 40.7% | 24.7% | 13.4% | |
| SG&A / Sales | 10.8% | 10.7% | 10.5% | 11.4% | 9.8% | |
| R&D / Sales | 2.1% | 2.9% | 3.3% | 3.5% | 3.5% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 3.4% | 3.6% | 3.9% | 4.8% | 5.6% | |
| Days sales outstanding | 174d | 175d | 176d | 137d | 120d | |
| Days payables outstanding | 119d | 105d | 136d | 132d | 104d | |
| Operating cycle | 295d | 287d | 301d | 254d | 214d | |
| Cash conversion cycle | 176d | 182d | 165d | 123d | 110d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-11 Stevanato Group Q2 Earnings Call Highlights Stevanato Group (NYSE: STVN) reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary. Revenue for the quarter reached €302 million, up 8% both on a reported and constant-currency
- 2026-08-09 Stevanato Group Q2 Earnings Call Highlights Stevanato Group NYSE: STVN reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary.
- 2026-08-05 Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes" Stevanato (STVN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 2026-08-04 Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript
- 2026-08-04 Stevanato Group (STVN) Q2 Earnings Top Estimates Stevanato Group (STVN) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.12 per share a year ago.
- 2026-08-04 Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026 PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2026. Second Quarter of 2026 Highlights (comparisons to prior-year period) Revenue increased 8% to €302.0 million, with high-value solutions representing 45% of total revenue. Gross profit margin increase.
- 2026-07-30 Liraglutide Combination Products Incorporating Stevanato Group''s Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, today announced that liraglutide-based combination products incorporating Stevanato Group''s proprietary Alina® pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Mark.
- 2026-07-21 Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026 PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2026 on Tuesday, August 4, 2026, at 6:30 a.m. (EDT). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EDT) on Tuesday, August 4, 2026, to discu.
- 2026-06-11 Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside Stevanato Group is reiterated as a Buy, driven by robust Q1 results and a compelling long-term growth trajectory. The High-Value Solutions segment accelerated, now comprising 47% of sales, fueled by broad biologics and injectable therapies demand. Management attributed the slowdown in the Engineering segment to project timing and order delays rather than competitive pressure or deteriorating demand. Importantly, segment profitability improved despite lower volumes.
- 2026-06-09 2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now The shares of both stocks are down so far this year. Stevanato is benefiting from the need for GLP-1 injectables.